Inceptionr LLC Raises Stake in Roivant Sciences Ltd. $ROIV

Inceptionr LLC increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 98.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,059 shares of the company’s stock after buying an additional 32,703 shares during the period. Inceptionr LLC’s holdings in Roivant Sciences were worth $999,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ROIV. Goldman Sachs Group Inc. grew its stake in Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after acquiring an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Roivant Sciences by 30.2% during the second quarter. Envestnet Asset Management Inc. now owns 42,810 shares of the company’s stock worth $482,000 after purchasing an additional 9,936 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Roivant Sciences by 12.7% during the second quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after purchasing an additional 506,219 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its position in shares of Roivant Sciences by 330.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 104,458 shares of the company’s stock valued at $1,177,000 after purchasing an additional 80,206 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at $43,830,274.53. The trade was a 10.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $26.47, for a total value of $8,985,003.27. Following the completion of the transaction, the insider directly owned 19,148,664 shares of the company’s stock, valued at $506,865,136.08. This represents a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 13,118,014 shares of company stock worth $311,557,023. Company insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ROIV shares. Leerink Partners upped their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. HC Wainwright upped their price objective on shares of Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $28.81.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $29.53 on Tuesday. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $30.03. The company has a market capitalization of $21.13 billion, a price-to-earnings ratio of -25.24 and a beta of 1.17. The business has a 50-day moving average of $24.72 and a 200-day moving average of $20.28.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.